Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
about
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Poor response to platinum-base ...... on of BRAC1 and TYMS in NSCLC.
@en
Poor response to platinum-base ...... on of BRAC1 and TYMS in NSCLC.
@nl
type
label
Poor response to platinum-base ...... on of BRAC1 and TYMS in NSCLC.
@en
Poor response to platinum-base ...... on of BRAC1 and TYMS in NSCLC.
@nl
prefLabel
Poor response to platinum-base ...... on of BRAC1 and TYMS in NSCLC.
@en
Poor response to platinum-base ...... on of BRAC1 and TYMS in NSCLC.
@nl
P2093
P2860
P356
P1476
Poor response to platinum-base ...... on of BRAC1 and TYMS in NSCLC.
@en
P2093
Hongxuan Zhou
Juxiang Chen
Pinghuai Shi
Xianqing Shi
Xiaodong Fei
Xiaoxing Tao
Yanfeng Yang
P2860
P356
10.1177/0300060515607383
P577
2016-01-05T00:00:00Z